6:44 PM
 | 
Mar 14, 2005
 |  BC Extra  |  Clinical News

Astralis' Psoraxine fails Phase II

ASTR's Psoraxine missed the primary endpoint of PASI score improvements in a double-blind, placebo-controlled, U.S. Phase...

Read the full 58 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >